{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:27:45Z","timestamp":1776868065782,"version":"3.51.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002550"],"award-info":[{"award-number":["UL1TR002550"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002550"],"award-info":[{"award-number":["UL1TR002550"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI135995"],"award-info":[{"award-number":["U19AI135995"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ability to identify who does or does not experience the intended immune response following vaccination could be of great value in not only managing the global trajectory of COVID-19 but also helping guide future vaccine development. Vaccine reactogenicity can potentially lead to detectable physiologic changes, thus we postulated that we could detect an individual\u2019s initial physiologic response to a vaccine by tracking changes relative to their pre-vaccine baseline using consumer wearable devices. We explored this possibility using a smartphone app-based research platform that enabled volunteers (39,701 individuals) to share their smartwatch data, as well as self-report, when appropriate, any symptoms, COVID-19 test results, and vaccination information. Of 7728 individuals who reported at least one vaccination dose, 7298 received an mRNA vaccine, and 5674 provided adequate data from the peri-vaccine period for analysis. We found that in most individuals, resting heart rate (RHR) increased with respect to their individual baseline after vaccination, peaked on day 2, and returned to normal by day 6. This increase in RHR was greater than one standard deviation above individuals\u2019 normal daily pattern in 47% of participants after their second vaccine dose. Consistent with other reports of subjective reactogenicity following vaccination, we measured a significantly stronger effect after the second dose relative to the first, except those who previously tested positive to COVID-19, and a more pronounced increase for individuals who received the Moderna vaccine. Females, after the first dose only, and those aged &lt;40 years, also experienced a greater objective response after adjusting for possible confounding factors. These early findings show that it is possible to detect subtle, but important changes from an individual\u2019s normal as objective evidence of reactogenicity, which, with further work, could prove useful as a surrogate for vaccine-induced immune response.<\/jats:p>","DOI":"10.1038\/s41746-022-00591-z","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T06:03:39Z","timestamp":1650348219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2208-7912","authenticated-orcid":false,"given":"Giorgio","family":"Quer","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-6537","authenticated-orcid":false,"given":"Matteo","family":"Gadaleta","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-0842","authenticated-orcid":false,"given":"Jennifer M.","family":"Radin","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-5982","authenticated-orcid":false,"given":"Kristian G.","family":"Andersen","sequence":"additional","affiliation":[]},{"given":"Katie","family":"Baca-Motes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-7094","authenticated-orcid":false,"given":"Edward","family":"Ramos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1478-4729","authenticated-orcid":false,"given":"Eric J.","family":"Topol","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9256-7914","authenticated-orcid":false,"given":"Steven R.","family":"Steinhubl","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"591_CR1","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","volume":"69","author":"SE Oliver","year":"2020","unstructured":"Oliver, S. E. et al. The advisory committee on immunization practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States, December 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1922\u20131924 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"591_CR2","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","volume":"69","author":"SE Oliver","year":"2021","unstructured":"Oliver, S. E. et al. The advisory committee on immunization practices' interim recommendation for use of Moderna COVID-19 vaccine-United States, December 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1653\u20131656 (2021).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"591_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.15585\/mmwr.mm7009e4","volume":"70","author":"SE Oliver","year":"2021","unstructured":"Oliver, S. E. et al. The advisory committee on immunization practices\u2019 interim recommendation for use of Janssen COVID-19 vaccine-United States, February 2021. MMWR Morb. Mortal. Wkly Rep. 70, 329\u2013332 (2021).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"591_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"591_CR5","doi-asserted-by":"publisher","unstructured":"Aran, D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.02.05.21251139 (2021).","DOI":"10.1101\/2021.02.05.21251139"},{"key":"591_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"591_CR7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N. Engl J. Med. 384, 1824\u20131835 (2021).","journal-title":"N. Engl J. Med."},{"key":"591_CR8","unstructured":"Thompson, M. G. et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers\u2014Eight U.S. Locations. MMWR Morb. Mortal. Wkly. Rep. ePub 70 (2021)."},{"key":"591_CR9","doi-asserted-by":"publisher","first-page":"e00084","DOI":"10.1128\/CMR.00084-18","volume":"32","author":"P Zimmermann","year":"2019","unstructured":"Zimmermann, P. & Curtis, N. Factors that influence the immune response to vaccination. Clin. Microbiol. Rev. 32, e00084\u201318 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"591_CR10","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1001\/archinte.1994.00420160048006","volume":"154","author":"GA Poland","year":"1994","unstructured":"Poland, G. A. & Jacobson, R. M. Failure to reach the goal of measles elimination: apparent paradox of measles infections in immunized persons. Arch. Intern. Med. 154, 1815\u20131820 (1994).","journal-title":"Arch. Intern. Med."},{"key":"591_CR11","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474\u20131484 (2021).","journal-title":"N. Engl. J. Med."},{"key":"591_CR12","unstructured":"NIH. V-safe after vaccination health checker. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/vsafe.html. (NIH, 2021)."},{"key":"591_CR13","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1001\/jama.2021.5374","volume":"325","author":"J Chapin-Bardales","year":"2021","unstructured":"Chapin-Bardales, J., Gee, J. & Myers, T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA 325, 2021\u20132202 (2021).","journal-title":"JAMA"},{"key":"591_CR14","unstructured":"CDC. Safety monitoring of COVID-19 vaccine booster doses among adults. https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7107e1.htm. (2022)."},{"key":"591_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9, C., Laup\u00e8ze, B., Del Giudice, G., Didierlaurent, A. M. & Tavares Da Silva, F. The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines 4, 39 (2019).","journal-title":"NPJ Vaccines"},{"key":"591_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","volume":"398","author":"A Flaxman","year":"2021","unstructured":"Flaxman, A. et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 398, 981\u2013990 (2021).","journal-title":"Lancet"},{"key":"591_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/vaccines10020264","volume":"10","author":"AE Mason","year":"2022","unstructured":"Mason, A. E. et al. Metrics from wearable devices as candidate predictors of antibody response following vaccination against COVID-19: data from the second tempredict study. Vaccines 10, 264 (2022).","journal-title":"Vaccines"},{"key":"591_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41591-020-1123-x","volume":"27","author":"G Quer","year":"2021","unstructured":"Quer, G. et al. Wearable sensor data and self-reported symptoms for COVID-19 detection. Nat. Med. 27, 73\u201377 (2021).","journal-title":"Nat. Med."},{"key":"591_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-021-00533-1","volume":"4","author":"M Gadaleta","year":"2021","unstructured":"Gadaleta, M. et al. Passive detection of COVID-19 with wearable sensors and explainable machine learning algorithms. NPJ Digital Med. 4, 166 (2021).","journal-title":"NPJ Digital Med."},{"key":"591_CR20","doi-asserted-by":"crossref","unstructured":"Mathioudakis, A. G. et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life (Basel) 11, 249 (2021).","DOI":"10.3390\/life11030249"},{"key":"591_CR21","unstructured":"CDC. The Janssen COVID-19 vaccine\u2019s local reactions, systemic reactions, adverse events, and serious adverse events. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/janssen\/reactogenicity.html. (2021)."},{"key":"591_CR22","doi-asserted-by":"publisher","first-page":"e0227709","DOI":"10.1371\/journal.pone.0227709","volume":"15","author":"G Quer","year":"2020","unstructured":"Quer, G., Gouda, P., Galarnyk, M., Topol, E. J. & Steinhubl, S. R. Inter- and intraindividual variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time of year: retrospective, longitudinal cohort study of 92,457 adults. PLoS ONE 15, e0227709 (2020).","journal-title":"PLoS ONE"},{"key":"591_CR23","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1001\/jamainternmed.2020.2834","volume":"180","author":"SJ Jaiswal","year":"2020","unstructured":"Jaiswal, S. J. et al. Association of sleep duration and variability with body mass index: sleep measurements in a large US population of wearable sensor users. JAMA Int. Med. 180, 1694\u20131696 (2020).","journal-title":"JAMA Int. Med."},{"key":"591_CR24","doi-asserted-by":"publisher","first-page":"e2004285","DOI":"10.1371\/journal.pbio.2004285","volume":"16","author":"WK Lim","year":"2018","unstructured":"Lim, W. K. et al. Beyond fitness tracking: the use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. PLoS Biol. 16, e2004285 (2018).","journal-title":"PLoS Biol."},{"key":"591_CR25","doi-asserted-by":"publisher","first-page":"e2001402","DOI":"10.1371\/journal.pbio.2001402","volume":"15","author":"X Li","year":"2017","unstructured":"Li, X. et al. Digital health: tracking physiomes and activity using wearable biosensors reveals useful health-related information. PLoS Biol. 15, e2001402 (2017).","journal-title":"PLoS Biol."},{"key":"591_CR26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41551-020-00640-6","volume":"4","author":"T Mishra","year":"2020","unstructured":"Mishra, T. et al. Pre-symptomatic detection of COVID-19 from smartwatch data. Nat. Biomed. Eng. 4, 1208\u20131220 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"591_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","volume":"10","author":"TD Querec","year":"2009","unstructured":"Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116\u2013125 (2009).","journal-title":"Nat. Immunol."},{"key":"591_CR28","doi-asserted-by":"crossref","unstructured":"Nakaya, H. I. & Pulendran, B. Vaccinology in the era of high-throughput biology. Philos. Trans. R Soc. Lond B Biol. Sci. 370, 20140146 (2015).","DOI":"10.1098\/rstb.2014.0146"},{"key":"591_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med"},{"key":"591_CR30","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2021.04.003","volume":"2","author":"S Kalimuddin","year":"2021","unstructured":"Kalimuddin, S. et al. Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset. Med 2, 682\u2013688.e4 (2021).","journal-title":"Med"},{"key":"591_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nri.2016.125","volume":"17","author":"P Brodin","year":"2017","unstructured":"Brodin, P. & Davis, M. M. Human immune system variation. Nat. Rev. Immunol. 17, 21\u201329 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"591_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","volume":"21","author":"JR Teijaro","year":"2021","unstructured":"Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195\u2013197 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"591_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"591_CR34","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316\u20131327 (2017).","journal-title":"Mol. Ther."},{"key":"591_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SHK.0000000000000276","volume":"43","author":"GN Herlitz","year":"2015","unstructured":"Herlitz, G. N. et al. Physiologic variability at the verge of systemic inflammation: multiscale entropy of heart rate variability is affected by very low doses of endotoxin. Shock 43, 133\u2013139 (2015).","journal-title":"Shock"},{"key":"591_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee, J. et al. First month of COVID-19 vaccine safety monitoring-United States, December 14, 2020-January 13, 2021. MMWR Morb. Mortal. Wkly Rep. 70, 283\u2013288 (2021).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"591_CR37","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/jama.2021.15125","volume":"326","author":"D Steensels","year":"2021","unstructured":"Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA 326, 1533\u20131535 (2021).","journal-title":"JAMA"},{"key":"591_CR38","doi-asserted-by":"publisher","unstructured":"Puranik, A. et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.06.21261707 (2021).","DOI":"10.1101\/2021.08.06.21261707"},{"key":"591_CR39","doi-asserted-by":"publisher","first-page":"e2124331","DOI":"10.1001\/jamanetworkopen.2021.24331","volume":"4","author":"NE Richards","year":"2021","unstructured":"Richards, N. E. et al. Comparison of SARS-CoV-2 antibody response by age among recipients of the BNT162b2 vs the mRNA-1273 vaccine. JAMA Netw. Open 4, e2124331\u2013e2124331 (2021).","journal-title":"JAMA Netw. Open"},{"key":"591_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","volume":"27","author":"JE Ebinger","year":"2021","unstructured":"Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981\u2013984 (2021).","journal-title":"Nat. Med"},{"key":"591_CR41","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2666-7568(20)30011-8","volume":"1","author":"LS Cox","year":"2020","unstructured":"Cox, L. S. et al. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. Lancet Healthy Longev. 1, e55\u2013e57 (2020).","journal-title":"Lancet Healthy Longev."},{"key":"591_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc2104849","volume":"385","author":"EM White","year":"2021","unstructured":"White, E. M. et al. Incident SARS-CoV-2 infection among mRNA-vaccinated and unvaccinated nursing home residents. N. Engl J. Med. 385, 474\u2013476 (2021).","journal-title":"N. Engl J. Med."},{"key":"591_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0124-6","volume":"4","author":"T Potluri","year":"2019","unstructured":"Potluri, T. et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines 4, 29 (2019).","journal-title":"NPJ Vaccines"},{"key":"591_CR44","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","volume":"385","author":"VG Hall","year":"2021","unstructured":"Hall, V. G. et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 385, 1244\u20131246 (2021).","journal-title":"N. Engl. J. Med."},{"key":"591_CR45","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/archinte.1986.00360180179026","volume":"146","author":"J Karjalainen","year":"1986","unstructured":"Karjalainen, J. & Viitasalo, M. Fever and cardiac rhythm. Arch. Intern. Med. 146, 1169\u20131171 (1986).","journal-title":"Arch. Intern. Med."},{"key":"591_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nri1369","volume":"4","author":"PA Bryant","year":"2004","unstructured":"Bryant, P. A., Trinder, J. & Curtis, N. Sick and tired: does sleep have a vital role in the immune system? Nat. Rev. Immunol. 4, 457\u2013467 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"591_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00044011-200626060-00004","volume":"26","author":"R Bettis","year":"2006","unstructured":"Bettis, R. et al. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin. Drug Investig. 26, 329\u2013340 (2006).","journal-title":"Clin. Drug Investig."},{"key":"591_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1220-z","volume":"17","author":"SC Rivera","year":"2019","unstructured":"Rivera, S. C. et al. The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis. Health Qual. Life Outcomes 17, 156 (2019).","journal-title":"Health Qual. Life Outcomes"},{"key":"591_CR49","doi-asserted-by":"publisher","first-page":"e205867","DOI":"10.1001\/jamanetworkopen.2020.5867","volume":"3","author":"SK Bell","year":"2020","unstructured":"Bell, S. K. et al. Frequency and types of patient-reported errors in electronic health record ambulatory care notes. JAMA Netw. Open 3, e205867\u2013e205867 (2020).","journal-title":"JAMA Netw. Open"},{"key":"591_CR50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch, E. et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318, 197\u2013198 (2017).","journal-title":"JAMA"},{"key":"591_CR51","doi-asserted-by":"publisher","first-page":"106424","DOI":"10.1016\/j.chb.2020.106424","volume":"111","author":"E Beaunoyer","year":"2020","unstructured":"Beaunoyer, E., Dup\u00e9r\u00e9, S. & Guitton, M. J. COVID-19 and digital inequalities: reciprocal impacts and mitigation strategies. Comput. Hum. Behav. 111, 106424 (2020).","journal-title":"Comput. Hum. Behav."},{"key":"591_CR52","unstructured":"Vogels, E. A. About one-in-five Americans use a smart watch or fitness tracker, https:\/\/www.pewresearch.org\/fact-tank\/2020\/01\/09\/about-one-in-five-americans-use-a-smart-watch-or-fitness-tracker\/ (2020)."},{"key":"591_CR53","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.7326\/M21-1451","volume":"174","author":"CM Connolly","year":"2021","unstructured":"Connolly, C. M. et al. Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series. Ann. Int. Med. 174, 1332\u20131334 (2021).","journal-title":"Ann. Int. Med"},{"key":"591_CR54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00031305.1980.10483031","volume":"34","author":"SR Searle","year":"1980","unstructured":"Searle, S. R., Speed, F. M. & Milliken, G. A. Population marginal means in the linear model: an alternative to least squares means. Am. Statistician 34, 216\u2013221 (1980).","journal-title":"Am. Statistician"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00591-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T08:51:33Z","timestamp":1726995093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00591-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1038\/s41746-022-00591-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.03.21256482","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"13 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.S. is employed by PhysIQ. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}